Crossmark

Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis

Crossref DOI link: https://doi.org/10.1186/s12885-018-4011-8

Published Online: 2018-01-31

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Shunli

Peng, Hong

Wang, Ye

Xu, Ming

Lin, Manxia

Xie, Xiaoyan

Peng, Baogang

Kuang, Ming
Funding

Funding for this research was provided by:

the Fundamental Research Funds for the Central Universities (09ykpy30, 15ykpy15)

the Science and Technology Project of Guangzhou (2014Y2-00129)

Natural Science Foundation of Guangdong Province (2014A030313108)

National Natural Science Foundation of China (81272312, 81071892)
More Information

Article History

Received: 4 October 2016

Accepted: 21 January 2018

First Online: 31 January 2018

Ethics approval and consent to participate

: This study was performed according to the guidelines of the Helsinki Declaration. It was registered and approved by the ethics committee at The First Affiliated Hospital of Sun Yat-sen University. All patients provided written informed consent before treatment.

: N/A.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.